Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
Current reports
8-K
Departure of Directors or Certain Officers
26 Apr 24
8-K
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
5 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
IO Biotech Announces 2023 Third Quarter Results
13 Nov 23
8-K
IO Biotech Announces 2023 Second Quarter Results
11 Aug 23
8-K
IO Biotech, Inc. Announces $75 Million Private Placement Financing
7 Aug 23
8-K
IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
18 Jul 23
8-K
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
14 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
IO Biotech Announces 2023 First-Quarter Results
11 May 23
Registration and prospectus
S-8
Registration of securities for employees
11 Mar 24
424B2
Prospectus for primary offering
12 Sep 23
S-3
Shelf registration
30 Aug 23
424B2
Prospectus for primary offering
15 Feb 23
S-8
Registration of securities for employees
6 Feb 23
S-3
Shelf registration
3 Feb 23
S-8
Registration of securities for employees
8 Feb 22
424B4
Prospectus supplement with pricing info
8 Nov 21
FWP
Free writing prospectus
5 Nov 21
S-1MEF
Registration of additional securities for an S-1
4 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
Other
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
6 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
EFFECT
Notice of effectiveness
13 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23
UPLOAD
Letter from SEC
8 Feb 23
EFFECT
Notice of effectiveness
5 Nov 21
SEC STAFF
SEC staff action: Order
5 Nov 21
CERT
Certification of approval for exchange listing
4 Nov 21
CORRESP
Correspondence with SEC
2 Nov 21
Ownership
4
Mai-Britt Zocca
18 Mar 24
4
Amy Sullivan
18 Mar 24
4
Devin Whittemore Smith
18 Mar 24
4
Brian Burkavage
18 Mar 24
4
Qasim Iftikhar Ahmad
18 Mar 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13D/A
Novo Holdings A/S
13 Feb 24
4
Change in insider ownership
13 Feb 24
SC 13G/A
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24